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Several human retroviruses have been discovered in the pastdecade, themajorityofwhich have
been implicated as etiological agents of severe disease entities. Thus, there is a clear need for
accurate identification of human retroviruses in the laboratory. In this review, the classification
and general properties ofhuman retroviruses are outlined. Methods for detecting the presence of
antibodies are reviewed. In addition, the principles of methods used for isolating and identifying
retroviruses arediscussed. Finally, techniques which detect the presenceofretroviruses directly in
clinical specimens without prior amplification in culture are summarized. Clearly, the ability to
differentiate and recognize the different types ofretrovirus is important for the proper treatment
ofdiseases caused by these viruses.
INTRODUCTION
Retroviruses have been thrust into the spotlight in the past five years because ofthe
epidemic produced by its most notorious member, the human immunodeficiency virus
type 1 (HIV-1). Other retroviruses such as HIV type 2 (HIV-2) and the human
T-leukemia virus type I (HTLV-I) have also carried out their deadly activity, but on a
less dramatic scale. There is little doubt that the retroviruses have made their mark
among the infectious diseases. Consequently, there is a clear need to differentiate and
understand the methods used to identify each ofthe viruses in the laboratory.
These retroviruses as a class are characterized by the possession of a RNA genome
and a reverse transcriptase enzyme. They also share a similar structure, consisting ofa
lipid membrane containing antigenic glycoproteins which encloses an inner protein
core containing other antigenic proteins, two RNA strands, and the reverse transcrip-
tase. In contrast to retroviruses of other species, the human retroviruses do not infect
reproductive cells; thus, they are not transmitted endogenously to offspring. Instead,
transmission is exogenous, as a transmissible, infectious agent.
The purpose of this paper is to review how the various human retroviruses differ
from each other insofar as laboratory diagnosis is concerned. First, nomenclature,
disease association, and general characteristics are discussed. Second, tests for the
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TABLE 1
Nomenclature of Human Retroviruses
Year
Virus Reported
Group Characteristic Name [References] Disease Association
Human immunodefi- Cytopathic HIV-la 1983 [1-4] Acquired immune deficiency syn-
ciency virus (HIV) drome
HIV-2 1986 [5] Acquired immune deficiency syn-
drome
Human T-cell leuke- Transforming HTLV-I 1980 [6] Adult T-cell leukemia/lymphoma
mia/lymphoma virus (ATLL)
(HTLV) Tropical spastic paraparesis (TSP)
HTLV-I-associated myelopathy
(HAM)
HTLV-II 1982 [14] Not establishedb
HTLV-III 1983 [1-4] See HIV-l
HTLV-IV 1986 [18] Nonec
HTLV-V 1987 [20] Notestablishedd
aPreviously called HTLV-III, LAV, or ARV
bIsolated from patients with hairy-cell leukemia
cThisvirus was initially thought to besimilar to HIV-2. Subsequently, it was found to be indistinguishable
from the simian immunodeficiency virus [19]
dIsolated from a patient with cutaneous T-lymphoma/leukemia
demonstration ofantibodies are reviewed. Finally, principles of retrovirus culture and
direct detection methods are summarized.
THE TWO MAJOR GROUPS OF HUMAN RETROVIRUSES
Nomenclature and Disease Association
Human retroviruses are of two major classes, distinguished by their primary patho-
logic effects on T cells (Table 1). Cytopathic retroviruses, which have been termed
human immunodeficiency viruses (HIV), cause cell death and result in immunodefi-
ciency. HIV-1, the first retrovirus found to be the etiologic agent of the acquired
immunodeficiency syndrome (AIDS), was previously called human immunodeficiency
virus (HIV), human T-leukemia virus type III (HTLV-III), lymphadenopathy-
associated virus (LAV) and AIDS-associated retrovirus (ARV) [1-4]. The human im-
munodeficiency virus type 2 (HIV-2), previously named lymphadenopathy-associated
virus type 2 (LAV-2), was isolated in 1986 from AIDS patients in West Africa [5].
The second major group of human retrovirus comprises transforming viruses. The
human T-leukemia virus type I (HTLV-I), the first human retrovirus to be identified,
has been implicated as the causative agent of adult T-cell leukemia-lymphoma [6-8]
and tropical spastic paraparesis (TSP) or HTLV-I-associated myelopathy (HAM)
[9-13]. HTLV-II was originally isolated from a patient with hairy-cell leukemia [14].
The implication of HTLV-II in a specific disease has been unclear because HTLV-II
has been isolated from a total ofonly four patients [14-17]; two of these patients had
hairy-cell leukemia [14,15]. Another retrovirus, initially named HTLV-IV, was
isolated in West Africa in 1986 [18]. Subsequently, it was found that HTLV-IV
isolates were indistinguishable from simian immunodeficiency virus isolates and
were not independent viral isolates [19]. In 1987, a new distinct human retrovirus
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TABLE 2
Comparison of Cytopathic and Transforming
Retroviruses of Humans
1. Similarities
RNA genome
Reverse transcriptase
Integration ofviral genome into host DNA
Structure
Genomic organization
Infection ofT cells
Latency
2. Differences
Nucleotide sequences
Antigenic reactivity
Effect on T cells
(HTLV-V) was isolated from a patient with a cutaneous T-cell lymphoma/leukemia
[20].
Comparison ofCytopathic and Transforming Retroviruses
Characteristics of cytopathic and transforming viruses are listed in Table 2 [6,7,
14,20,21]. In addition to similar structures, both groups ofretroviruses share a similar
genomic organization with three major structural genes (gag, env, and pol). Each of
these genes codes for a precursor protein, which isprocessed intooneormorestructural
elements. These genes are flanked by sequences called long terminal repeats or LTRs.
In addition, several genes that regulate the expression of other viral genes have been
identified. The HTLVs have one regulatory gene, called tat gene for transacting
activator; the protein productofthisgenemediates thetranscriptional activation ofthe
viral LTR and genes linked to it. The HIVs have at least three regulatory genes called
tat III, sor, and 3' orf. The tat IIIgene is a transactivator gene that produces a 14 kD
gene product. The functions of the sor and 3' orf genes are unclear at this time;
however, it is known that they code for 23 kD and 27 kD gene products, respectively.
Both groups ofviruses primarily infect a subset of T cells and some neural cells, and
they have a long incubation period.
Despite these similarities, the two groups of viruses are only distantly related, as
determined by comparisons of nucleotide sequence and protein cross-reactivity. The
genomes of HTLV-I, HTLV-II and HTLV-V are related; HTLV-I and HTLV-II
share approximately 50 percent of their genome. Likewise, HIV-1 and HIV-2 are
approximately 40 percent homologous. HTLVs, however, are not related to HIVs. As
noted before, the effects on cells of these two groups of virus are strikingly different,
since the cytopathic viruses usually kill the cells they infect and the transforming
viruses induce cell proliferation.
TESTS FOR THE DEMONSTRATION OF ANTIBODIES
Thedemonstration ofspecific antibodies toretroviruses can, in themajorityofcases,
provide adequate evidence of ongoing infection, as retroviral antibodies generally
persist for life. Enzyme-linked immunosorbent assays (ELISA) for the detection of
antibodies to retroviruses were initially developed to screen blood and blood products.
A serum that is found repeatedly positive by the ELISA screening test is further tested
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by a supplementary method to confirm the presence of specific antibodies. The major-
ity ofscreening and confirmatory tests make use ofviral antigens prepared by growing
the virus in culture; thus, antibodies to a mixture of viral proteins are probed in these
assays. Recently, novel methods that make use of recombinant HIV-1 antigens and
detect antibodies to one or more specific viral proteins have been described [22,23].
Screening Tests
The most frequently used assay, the ELISA, was developed for diagnosis of
HTLV-I, HIV-1, and HIV-2 infections in 1983, 1984, and 1987, respectively [24-26].
Eight ELISA kits for HIV-1 and three ELISA kits for HTLV-I are now licensed in the
U.S. for antibody testing. Although HIV-2 ELISA kits are available commercially,
they are not yet licensed in the U.S.
HTLV-I and HTLV-II are very closely related and thus exhibit extensive serologic
cross-reactivity. As a result, HTLV-I ELISA kits do not distinguish between HTLV-I
and HTLV-II antibodies. In contrast, the degree of immunologic cross-reactivity
between HTLV-I and HIV-1 in ELISAs appears to be very small, although some
antigenic relationship has been suggested [27]. HIV-1 antibody-positive patients have
been evaluated for reactivity to HTLV-I by ELISA [28] or by indirect immunofluores-
cence assay (IFA) [29]. Two of 35 patients were positive in the first study [28] and
none of 363 were positive in the second study [29].
Because ofthe high degree ofimmunologic cross-reactivity between the gag and the
pol gene products of HIV-1 and HIV-2 [5,30], a number of studies have determined
whether HIV-1 ELISAs could be used to detect antibodies to HIV-2 [31,32]. In one
study [31], 43 sera positive for HIV-2 antibody were tested by nine HIV-1 ELISAs.
The overall prevalence of positive results ranged between 28 and 93 percent. Most of
the ELISAs were less sensitive in detecting antibody to HIV-2 in sera from people with
AIDS-like disease than in sera from asymptomatic HIV-2-infected individuals[31]. A
number of reports, including two cases in the U.S., have suggested that anti HIV-1
ELISAs are inadequate for diagnosis of HIV-2 infections [33,34]; however, use of
peptide antigens representing a conserved region of the transmembrane protein allows
testing for type-specific antibodies against HIV in an ELISA [35,36]. Hence, specific
antibodies in sera from patients infected with HIV-1, HIV-2, or both viruses can be
identified.
Other screening tests have been used. They include passive hemagglutination for
HIV-1 and HTLV-I [37-39] and indirect immunofluorescence [29,40-42].
Confirmatory Tests
Antigens coded by genes of the various retroviruses can be serologically cross-
reactive in ELISA tests; thus it is important to utilize an assay that can discriminate
between antibodies to specific proteins. The most frequently used of these tests is the
Western blot test (WB). Other supplementary tests available include IFA and ra-
dioimmunoprecipitation (RIPA). In contrast to IFA, WB and RIPA detect antibodies
to the specific viral gene products that have been separated by gel electrophoresis.
Antibodies to retroviral gene products that are routinely used in laboratory diagnosis
are listed in Table 3. Products of the tat gene are regulatory proteins which affect the
level ofexpression ofother viral genes. For HTLV-I, the 40 kDa protein encoded by the
tat gene is essential for the transforming effect of the virus, and the antibody is
detectable in the serum of HTLV-I-infected patients. Antibodies to the gene products
ofthe tat, sor, and 3' orfgenes ofHIV-1 have been detected in some patients but do not
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TABLE 3
Antibodies to Gene Products of Human Retroviruses That Can Be Detected
in Sera from Infected Individuals
Gene Products of
Major General Description
Genes ofGene Products HIV-1 HIV-2 HTLV-I/HTLV-IT
Core Precursor ofgagprotein p55 p53-55 p53
(gag) gagprotein p24 p25 p24
gagprotein p18 p16 p19
Envelope Precursor of envglycoprotein gpl6O gpl30-140 gp61
(env) Outer envglycoprotein gpl2O gplOS gp46
Transmembrane envglycoprotein gp4l gp36 p21
Polymerase Reverse transcriptase component p65 p68 p62
(pol) Reverse transcriptase component pS1 p32
Endonuclease component p31 p33 p14
Trans-Activator p4OX(HTLV-I)
(tat) p37X(HTLV-II)
at present play a role in diagnosis. Antibodies to the HIV-1 3' orfregulatory factor
have been recently found to be present and to persist in seronegative individuals who
were infected with HIV-1 as demonstrated by polymerase chain reaction (PCR) DNA
amplification [43].
Although there are many similarities in the protein products of the various
retroviruses, cross-reactivity usually is detected only for the core proteins, particularly
p24. Indeed, in WBs, antibody-positive sera give a strong signal with the transmem-
brane glycoprotein of the corresponding serotype alone. For example, an HIV-2-
positive sera will often react weakly with p24 in an HIV-1 WB but will usually react
strongly with both core and envelope proteins on an HIV-2 WB. Examples of
reactivities of serum from HIV-1, HTLV-I, and dually infected individuals in HIV-1
and HTLV-I WBs are shown in Fig. 1. Neither the ELISA nor the WB for HTLV-I
can distinguish between antibody to HTLV-I and antibody to the closely related
HTLV-II. Criteria for calling a sample WB positive vary from laboratory to labora-
tory. It is generally accepted, however, that antibodies to at least one core and one
envelope protein should be present. In most cases, useofoneoftheconfirmation tests is
sufficient. In some situations, however, useofboth WB and RIPA is helpful because of
complementary features. Thus, the WB often favors the detection of core proteins,
whereas the RIPA favors thedetection ofenvelope proteins. Forexample, antibodies to
the HTLV-I gp6l and gp46 can be seen more easily using RIPA.
IFA has been used to confirm the presence of HIV-1 antibodies; various neoplastic
T-cell lines infected with HIV-1 including CEM, Hut 78, and H9 can beused [40-42].
HTLV-I-transformed cell lines, MT-1 and MT-2, or Molt-3 cells have been utilized
successfully in HTLV-I IFA [29,44]. An HTLV-TI-transformed cell line has also been
used in IFA [29]. Sera that reacted with HTLV-I were tested on HTLV-II slides, and
specimens were considered positive ifthey reacted with both antigens. Adsorption tests
determined whether antibody responses were more closely related to HTLV-I or to
HTLV-II [29].
ISOLATION AND IDENTIFICATION OF HUMAN RETROVIRUSES
The principles ofthe procedures used for isolating and identifying HIV-1 have been
outlined before [45]. Isolation and identification ofhuman retroviruses is a two-stage,
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gp160-
gp 120
p53-
gp46- FIG. 1. Reactivityofsera from HIV-
p55-. I and HTLV-I ELISA-positive patients
p4
- p36- with HIV-1 (lanes Al to A4) and
HTLV-I (lanes Bi to B4) proteins in
Western blots: Lanes Al and B3:
p32- serum from an HIV-I-positive, HTLV-
I-negative individual; Lanes BI
p24- and A3: serum from an HIV-i-nega-
p24 tive, HTLV-I-positive individu-
p 19- al; Lanes A2 and B2: serum from
an HIV-I-negative, HTLV-I-negative
lIB - individual; Lanes A4 and B4: se-
V18 rum from an HIV-1-postive, HTLV-
I-positive individual.
elaborate, and time-consuming procedure (Fig. 2). In the first stage, susceptible cell
cultures are co-cultivated with the patient specimen for several weeks. In the second
stage, viral enzymes or antigens that are released in culture supernatants or present in
the cells are identified.
Usefulness ofRetrovirus Isolation
Although diagnosis of retroviral infections is more easily obtained by detecting
antibodies in the patients' sera, management of patients can, in many circumstances,
be significantly improved if the presence of the virus can be demonstrated in the
patient. We have discussed before the need and value of HIV-1 isolation (1) for
confirming the diagnosis of HIV-1 in individuals who have no detectable antibodies or
in whom the significance ofseropositivity is unclear; (2) for disease staging; and (3) for
monitoring antiviral therapy [45]. Isolation ofother retroviruses may help to confirm
the diagnosis of retrovirus infections in cases where antibody results are negative or
difficult to interpret. Most important, virus isolation attempts allow the demonstration
of retroviruses as causative agents of new disease entities and the discovery of new
viruses.
Cytopathogenicity andHost CellRange
Primary lymphocyte cultures, prepared from the blood of normal donors and
stimulated with a mitogen such as phytohemagglutinin and a T-cell growth factor such
as interleukin 2, are the most sensitive for the isolation of the cytopathic retroviruses
[45]. Because HIV-1 and HIV-2 produce cell death, fresh donor lymphocytes have to
be added weekly to the cultures.
In contrast to the cytopathic retroviruses, the transforming retroviruses eventually
do not require addition of fresh lymphocytes or T-cell growth factor for their growth.
Initially, cells from the patients are grown in vitro in the presence of T-cell growth
factors or cells from the patients are co-cultivated with stimulated donor lymphocytes.
HTLV-I-infected cells will continue to thrive without addition of fresh lymphocytes.
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Clinical specimen: Donor lymphocytes:
body fluid or separated stimulated and cultured
blood mononuclear cells
Culture in the
presence of
TRANSFORMING T-celIgrowth factors CYTOPATHIC
RETROVIRUSES RETROVIRUSES
Do notadd fresh donor cells Add fresh donor cells weekly
Remove T-cell growth factors Leave T-cell growth factors
Continuous cell growth Cytopathology
Identification of virus released in the supernatant
Reverse transcriptase Viral genome
Viral antigen
FIG. 2. Flow chart of various steps involved in isolation and identification of human
retroviruses.
After several weeks in culture, T-cell growth factors can be removed from the culture
media, as HTLV-I- and HTLV-II-infected cells do not require exogenous T-cell
growth factors for their continued growth. For both groups ofviruses, cell viability and
cytopathology should be monitored. In addition, the cell cultures are evaluated at
weekly intervals throughout the culture period for virus expression and release.
Human retroviruses are known to infect human cells which bear the CD4 surface
antigen. This antigen is a marker for the helper inducer T-cell subset. HIVs have been
shown to infect T lymphocytes, monocytes and macrophages, and B lymphocytes and
cells ofneuronal or glial origin, some but not all ofwhich bear CD4 [21]. HTLVs can
readily infect helper inducer T lymphocytes, but much less is known about their ability
to grow in other cell types. Cells infected with HIV-1 or HIV-2 will show, to various
degrees, a characteristic cytopathic effect consisting of multinucleated giant syncytial
cells with ring formation. These cells die over a period of a few days. Many HIV-1
isolates possess markedly different abilities to replicate and induce cytolysis in dif-
ferent host cell types [35,46-511. Syncytium-inducing isolates often have higher
infectivity than isolates that do not induce syncytia. HIV-1-infected individuals may
carry multiple HIV-1 genotypes with distinct cytopathogenic and cell tropism [52].
Recently, a new HIV-2 isolate thatdid not causecytopathic effect in susceptibleT cells
was recovered from an Ivory Coast patient [50]. HTLV-I and HTLV-II donot produce
cell death; instead, these viruses will generally transform T4 cells in five to ten weeks.
HTLV-I can also show syncytia formation [53].
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Methods ofRetrovirus Identification
Methods of identification rely most often on the demonstration of viral proteins or
viral genome in supernatants of infected cells. Less frequently, identification of viral
antigens or viral genome in infected cells is attempted. The measurement of reverse
transcriptase is broadly utilized as the primary method for the detection of all ret-
roviruses. The assay is based on identifying the enzyme's capacity to assemble DNA
from a RNA template. For HIV-1 and HIV-2, it takes, in general, 7 to 28 days of
co-cultivation of patients' specimens with susceptible cells to accumulate sufficient
enzyme for detectability in the supernatant. Release ofdetectable reverse transcriptase
activity into the supernatants ofHTLV-I-infected cells can take much longer, up to 12
weeks [54]. The reverse transcriptase assay does not allow for the identification ofeach
type of retrovirus.
Detection of specific viral antigens allows for identification of each type of ret-
rovirus. Antigen capture ELISA kits for detection of HIV-1 antigens are available;
however, kits for detection of the other retrovirus antigens are not available commer-
cially.
Other methods of retrovirus identification involve the identification of retrovirus
nucleic acids. Dot blot hybridization techniques have been employed to identify HIV-1
[55] and HIV-2 [56]. In this assay, cytoplasmic RNA prepared from cultured cells is
denatured, spotted on nylon filter, and detected with labeled viral DNA. In addition,
PCR has been used to monitor cultures for the presence of proviral sequences of
HIV-1, HIV-2 [57,58], and HTLV-I [59,60]. The PCR takes advantage ofan enzyme
that uses a defined segment in a strand of DNA as a template for assembly of a
complementary strand. During each reaction, the number of DNA strands doubles.
The reaction takes only a few minutes and is repeated up to 40 times; a discrete strand
of DNA can therefore be amplified to as many as one million copies. A monoclonal
antibody solution hybridization assay for the measurement of viral RNA in patients'
specimens has also been described recently [61]. The assay involves a reaction in
solution between a biotinylated DNA probe and the putative RNA target in the
sample. Labeled hybrids are detected by using a solid-phase anti-biotin antibody and
an enzyme-labeled monoclonal antibody specific for DNA-RNA hybrids.
DIRECT DETECTION OF RETROVIRUSES
Methods for detecting retroviruses directly in cells or body fluids from infected
individuals are less cumbersome and faster than virus isolation procedures. Except for
the PCR method, however, they do not include amplification of the virus and thus tend
to be less sensitive than virus isolation. The antigen capture ELISA method has been
used to detect HIV-1 antigen in serum and cerebrospinal fluid [62]. In this assay,
antibodies that recognize epitopes of the viral protein are coated to beads or plates and
are used to catch the antigen. A positive reaction is identified with a probe antiviral
antibody and a labeled secondary antibody. This method is useful for early detection of
HIV-1 infection because antigenemia can be demonstrated as early as two weeks after
infection, one month prior to the appearance of antibodies; however, antigen detection
systems cannot detect virus that has entered a latent state with low or absent expression
of structural proteins.
The use of nucleic acid hybridization techniques has the advantage of not requiring
production of proteins by the virus. HIV-1 has been detected directly within lympho-
cytes, macrophages, and other cells by in situ hybridization [63,64]. The recently
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developed PCR method allows for the detection ofinfectious agents that are present in
cells at very low copy numbers and that are not detectable by current methodologies.
The PCR DNA amplification technique has been utilized to identify the presence of
proviral sequences of HIV-1 directly in DNA isolated from peripheral blood mononu-
clear cells of seropositive individuals [58]. HTLV-I has been detected in HTLV-I
seronegative patients with T-cell leukemia [59] and in the blood of patients with
chronic progressive myelopathy [13]. In addition, proviral sequences from HIV-1 and
HIV-2 have been detected by PCR in a person dually infected [57].
CONCLUSION
Several human retroviruses that are capable ofproducing significant morbidity and
mortality have been discovered in recent years. Laboratory identification of the par-
ticular retroviruses involved in the various diseases is important to improve patient
management. It is necessary for laboratories to consider the differential diagnosis of
the various types of human retroviruses because the number of pathogenic human
retroviruses has increased in recent years and because mixed infections with HIV-1
and HTLV-I [54,65,66] and with HIV-1 and HIV-2 [57] have been reported. With
continuing advances in antiviral therapy and increased knowledge ofthe pathogenesis
of these viruses, the correct identification of the viral etiology will have more im-
mediate clinical application.
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